Inogen Inc — fact timeline

Andrew (Andy) Reding was appointed as Executive Vice President, Chief Operating Officer at Inogen Inc.

“appointed Andrew (Andy) Reding to serve as Executive Vice President, Chief Operating Officer (“COO”) of the Company, effective July 6, 2026.”

Inogen Inc shareholders rejected Amendment to Declassify the Board.

“The Company’s stockholders did not approve the amendment to the Company's Thirteenth Amended and Restated Certificate of Incorporation to declassify the Board. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 17,883,761 154,379 235,085 2,571,716”

Inogen Inc shareholders approved Approval of the Amended and Restated 2023 Equity Incentive Plan.

“The Company’s stockholders approved the adoption of the Amended and Restated 2023 Equity Incentive Plan. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 16,208,966 2,009,937 54,322 2,571,716”

Inogen Inc shareholders approved Advisory Vote on Executive Compensation.

“The Company’s stockholders approved the named executive officers’ compensation as disclosed in the Proxy. The votes regarding the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 17,316,134 921,787 35,304 2,571,716”

Inogen Inc shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-12-31 meeting.

“The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes 20,395,716 407,035 42,190 —”

Inogen Inc shareholders approved Election of Class III Directors.

“The following nominees were elected to serve as Class III directors, to hold office until the Company’s 2029 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Glenn Boehnlein 17,324,463 948,762 2,571,716 Mira Sahney 13,276,829 4,996,396 2,571,716”

Inogen Inc reported first quarter ended March 31, 2026 results: revenue $85.1 million, net income GAAP net loss for the first quarter of 2026 was $8.3 million. Guidance reaffirmed.

“total revenue in the first quarter of 2026 was $85.1 million”

Inogen Inc entered into Cooperation Agreement with Kent Lake Partners LP, Kent Lake PR LLC and Benjamin Natter (effective 2026-04-06).

“On April 6, 2026, the Company entered into a Cooperation Agreement (the “Cooperation Agreement”) with Kent Lake Partners LP (“Kent Lake”), Kent Lake PR LLC (“Kent Lake PR”) and Benjamin Natter”

Mira Kirti Sahney was appointed as Director at Inogen Inc.

“On January 31, 2025, the Board, upon recommendation of the Nominating and Governance Committee, appointed Mira Kirti Sahney to the Board, effective January 31, 2025.”

Thomas A. West resigned as Director at Inogen Inc.

“On January 30, 2025, Thomas A. West notified Inogen, Inc. (“the Company”) of his resignation as a member of the Board of Directors (the “Board”) of the Company, the Compliance Committee of the Board (the “Compliance Committee”), and the Nominating and Governance Committee of the Board (the “Nominating and Governance Committee”), in each case effective as of January 30, 2025.”

Jason Somer departed as Executive Vice President, General Counsel and Secretary at Inogen Inc.

“the Company and Jason Somer, Executive Vice President, General Counsel and Secretary of the Company, mutually determined that Mr. Somer would separate from the Company on July 19, 2024.”

Kevin P. Smith was appointed as Executive Vice President, Business Development, General Counsel and Secretary at Inogen Inc.

“On May 6, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Kevin P. Smith to serve as Executive Vice President, Business Development, General Counsel and Secretary of the Company, effective July 22, 2024.”

Jason Somer departed as Executive Vice President, General Counsel and Secretary at Inogen Inc.

“On July 2, 2024, Inogen, Inc. (the “Company”) and Jason Somer, Executive Vice President, General Counsel and Secretary of the Company, mutually determined that Mr. Somer would separate from the Company on July 19, 2024.”

Stanislav Glezer departed as Executive Vice President, R&D and Chief Medical Officer at Inogen Inc.

“Dr. Glezer’s role as an officer and employee of the Company ended effective April 11, 2024”

Inogen Inc reported quarter ended March 31, 2024 results: revenue $78.0 million, net income $14.6 million.

“while strengthening our market leading position. I am excited for the future of Inogen.” First Quarter 2024 Financial Results First quarter total revenue increased 8.1% to $78.0 million from $72.2 million in the first quarter of 2023, primarily driven by higher international and domestic business-to business sales, partially offset by lower direct-to-consumer”

Stanislav Glezer departed as Executive Vice President, R&D and Chief Medical Officer at Inogen Inc.

“On April 11, 2024, Inogen, Inc. (the “Company”) and Dr. Stanislav Glezer, Executive Vice President, R&D and Chief Medical Officer of the Company, mutually determined that Dr. Glezer would separate from the Company on or before May 3, 2024.”

Inogen Inc reported the fourth quarter and the full year ended December 31, 2023 results: revenue $75.9 million; full-year 2023 revenue of $315.7 million, net income GAAP net loss for the fourth quarter of 2023 was $26.6 million compared to GAAP net loss of $56.6 million in the fourth.

“Inogen Announces Fourth Quarter and Full-Year 2023 Financial Results Fourth quarter 2023 revenue of $75.9 million; full-year 2023 revenue of $315.7 million”

Michael Bourque was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Inogen Inc.

“On January 21, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Michael Bourque to serve as Executive Vice President, Chief Financial Officer and Treasurer (“CFO”) of the Company, effective March 4, 2024.”

Grégoire Ramade was appointed as Chief Commercial Officer at Inogen Inc.

“On January 2, 2024, the Board of Directors (“Board”) of Inogen, Inc. (the “Company”) appointed Grégoire Ramade to serve as Chief Commercial Officer (“CCO”) of the Company, effective January 2, 2024.”

Nabil Shabshab resigned as Director at Inogen Inc.

“Mr. Shabshab resigned from the Company’s board of directors, effective as of November 22, 2023”

Nabil Shabshab departed as other_named_officer at Inogen Inc.

“Mr. Shabshab’s role as an officer and employee of the Company ended effective November 10, 2023”

Nabil Shabshab departed as President and Chief Executive Officer at Inogen Inc.

“Mr. Shabshab's role as an officer and employee of the Company ended effective November 10, 2023.”

Kevin Smith was appointed as Class III director at Inogen Inc.

“appointed Mr. Smith to serve as a Class III director of the Company, effective November 10, 2023.”

Kevin Smith was appointed as President and Chief Executive Officer at Inogen Inc.

“appointed Kevin Smith to serve as President and Chief Executive Officer ("CEO") of the Company, effective November 10, 2023.”

Inogen Inc reported the quarter ended September 30, 2023 results: revenue $84.0 million, net income GAAP net loss of $45.7 million.

“the homecare setting, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 and Recent Business Highlights • Reported total revenue of $84.0 million, reflecting a decrease of 20.3% from the third quarter of 2022. • Completed acquisition of Physio-Assist SAS, expanding Inogen’s global respiratory care presence by addressing a”

Inogen Inc completed an acquisition involving Physio-Assist SAS for approximately $32,000,000 cash at closing subject to adjustment for the estimated net debt amount (closed 2023-09-14).

“clearance technique) for patients suffering from obstructive respiratory diseases. Pursuant to the terms of the Share Purchase Agreement, Inogen paid the Sellers approximately $32,000,000 cash at closing subject to adjustment for the estimated net debt amount of Physio-Assist SAS (subject to potential adjustment after closing following confirmation of the actual”

Michael K. Sergesketter was appointed as Chief Financial Officer at Inogen Inc.

“Effective as of September 11, 2023, the Company’s board of directors (the “Board”) appointed Michael K. Sergesketter to serve as the Company’s interim Executive Vice President, Chief Financial Officer and Treasurer.”

Kristin Caltrider departed as Chief Financial Officer at Inogen Inc.

“On September 1, 2023, Kristin Caltrider, Executive Vice President, Finance, Chief Financial Officer and Treasurer, notified Inogen, Inc. (the “Company”) of her intention to step down as an officer of the Company effective upon the date a new Executive Vice President, Chief Financial Officer and Treasurer commences employment, which will occur on September 11, 2023.”

George Parr departed as Executive Vice President and Chief Commercial Officer at Inogen Inc.

“the Company and George Parr, Executive Vice President and Chief Commercial Officer of the Company, mutually agreed that Mr. Parr would separate from the Company on or before July 31, 2023.”

Inogen Inc reported second quarter ended June 30, 2023 results: net income Adjusted net loss of $5.8 million.

“Adjusted net loss was $5.8 million compared to Adjusted net loss of $0.4 million in the second quarter of 2022.”

George Parr departed as Executive Vice President and Chief Commercial Officer at Inogen Inc.

“On July 27, 2023, Inogen, Inc. (the “Company”) and George Parr, Executive Vice President and Chief Commercial Officer of the Company, mutually determined that Mr. Parr would separate from the Company on or before July 31, 2023.”

Inogen Inc reported second quarter of 2023 results: revenue in the range of $83 million to $84 million.

“Inogen estimates preliminary, unaudited total revenue in the second quarter of 2023 to be in the range of $83 million to $84 million.”

Inogen Inc entered into Share Purchase Agreement with Mr. Adrien Mithalal, Mr. Jean-Sébastien Lantz, Mrs. Anne Reiser, CAAP Creation, Societe De Capital Risque Provencale Et Corse, Region Sud Investissement, Mérieux Participations 2, Relyens Innovation Santé and certain holders of exercisable securities identified therein valued at approximately $32,000,000 cash at closing (effective 2023-07-10).

“On July 10, 2023, Inogen, Inc., a Delaware corporation (“Inogen”), entered into a Share Purchase Agreement (the “Share Purchase Agreement”) with Mr. Adrien Mithalal, Mr. Jean-Sébastien Lantz, Mrs. Anne Reiser, CAAP Creation, Societe De Capital Risque Provencale Et Corse, Region Sud Investissement, Mérieux Participations 2, Relyens Innovation Santé and certain holders of exercisable securities identified therein (collectively, the “Sellers”).”

Inogen Inc reported the quarter ended March 31, 2023 results: revenue $72.2 million, net income GAAP net loss of $20.3 million.

“Inogen Announces First Quarter 2023 Financial Results Total Revenue of $72.2 Million In Line with Company Expectations Rental Revenue Year-over-Year Growth of 25% GOLETA, Calif., May 04, 2023 -- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2023.”

Thomas A. West was appointed as Director at Inogen Inc.

“On March 21, 2023, the Board, upon recommendation of the Nominating and Governance Committee, appointed Thomas A. West to the Board, effective April 1, 2023.”

Kristen Miranda resigned as Director at Inogen Inc.

“On March 19, 2023, Kristen Miranda notified Inogen, Inc. (“the Company”) of her resignation as a member of the Board of Directors (the “Board”) of the Company, the Compliance Committee of the Board (the “Compliance Committee”), and the Nominating and Governance Committee of the Board (the “Nominating and Governance Committee”), in each case effective as of March 31, 2023.”

Inogen Inc reported the full year ended December 31, 2022 results: revenue $377.2 million, net income $83.8 million.

“Total revenue of $377.2 million, up 5.4% versus 2021, primarily due to higher international business-to-business sales and rental revenue, partially offset by lower domestic business-to-business and direct-to-consumer sales. Total gross margin was 40.7% for the full year 2022 versus 49.3% in 2021. The decline was primarily driven by increased material costs related to premiums paid for semiconductor chips and sales channel mix. Additional impacts included higher cost of other materials and warranty costs as well as lower manufacturing productivity. This was partially offset by the impact of higher selling prices across all channels. Total operating expense for the full year was $238.8 million compared to $167.2 million for the full year 2021, representing an increase of 42.8%. Excluding the loss on disposal of intangible asset, operating expense increased 11.6%. The increased spend was primarily due to ongoing strategic investments required to position the Company for long-term sustain”

Inogen Inc reported the fourth quarter ended December 31, 2022 results: revenue $88.1 million, net income $56.6 million.

“Fourth quarter total revenue increased 15.3% to $88.1 million from $76.4 million in the fourth quarter of 2021, primarily due to growth in domestic business-to-business sales and rental revenue, partially offset by lower direct-to-consumer sales. Total gross margin was 33.5% in the fourth quarter of 2022 versus 50.5% in the comparative period in 2021. The decline was driven primarily by sales channel mix, increased material costs including premiums paid for components and higher warranty costs, partially offset by higher manufacturing productivity from increased production volumes. Total operating expense for the quarter was $88.0 million compared to $45.3 million in the fourth quarter of 2021, representing an increase of 94.3%. The current period expenses include a one-time loss on disposal of intangible asset of $52.2 million. Excluding this loss, operating expense decreased 20.9%, primarily due to the change in fair value of the New Aera earnout liability. GAAP net loss for the four”

Bart Sanford departed as Executive Vice President, Operations at Inogen Inc.

“On February 6, 2023, Inogen, Inc. (the “Company”) and Bart Sanford, Executive Vice President, Operations of the Company, mutually determined that Mr. Sanford would separate from the Company on or before March 1, 2023.”

Inogen Inc reported fourth quarter and full year ended December 31, 2022 results: revenue in the range of $87.5 million to $88.5 million. Guidance reaffirmed.

“for the fourth quarter and the full year ended December 31, 2022. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2022 to be in the range of $87.5 million to $88.5 million, representing year-over-year growth of 14.5% to 15.8%. Full year 2022 total preliminary, unaudited revenue is expected to be in the range of $376.7 million to”

Inogen Inc announced a impairment with charges of loss on asset disposal of its technology intangible assets of approximately $53.4 million and loss on inventory of $0.2 to $0.3 million affecting technology intangible assets related to Tidal Assist Ventilator (TAV) technology acquired from New Aera.

“In connection with the Disposal Determination, the Company estimates it will incur a loss on asset disposal of its technology intangible assets of approximately $53.4 million and loss on inventory of $0.2 to $0.3 million, partially offset by a decrease in the fair value of the Company’s New Aera earnout liability of approximately $13.6 to $13.7 million.”

Inogen Inc reported the quarter ended September 30, 2022 results: revenue $105.4 million, net income $9.5 million.

“Third quarter total revenue increased 13.2% to $105.4 million from $93.1 million in the third quarter of 2021, primarily driven by higher domestic business-to-business sales, as well as continued strength in the rental channel, partially offset by lower international business-to-business and direct-to-consumer sales. Total gross margin was 40.6% in the third quarter of 2022 versus 51.2% in the comparative period in 2021. The decline was driven primarily by increased material costs and unfavorable sales channel mix, partially offset by higher average selling prices. Total operating expense for the quarter was $53.1 million compared to $41.3 million in the third quarter of 2021, representing an increase of 28.5%. The increased spend was primarily due to ongoing strategic investments required to position the Company for long-term sustainable growth. Additionally, there was a non-cash decrease in the benefit from the change in fair value of the New Aera earnout liability. GAAP net loss for”

Inogen Inc: Amended and restated bylaws to revise director nomination procedures, stockholder meeting provisions, forum selection, board action by written consent, indemnification, and other updates to conform to Delaware law (effective 2022-10-27).

“On October 27, 2022, the Board of Directors (the “Board”) of the Company, acting upon the recommendation of the Nominating and Governance Committee of the Board, amended and restated the Company’s amended and restated bylaws, effective immediately.”

Loren McFarland departed as Director at Inogen Inc.

“On January 6, 2022, Loren McFarland informed Inogen, Inc. (the “Company”) that he will not stand for re-election at the Company’s 2022 annual meeting of stockholders.”